



# Invesco Global Health Care Fund

## Sectors

Data as of Dec. 31, 2011

### Investment objective and strategy

The fund seeks long-term growth of capital by investing in equity securities of health care companies throughout the world.

### Portfolio management

Derek Taner, Dean Dillard

### How does the fund fit into your portfolio?

- **Satellite position.** The fund is a sector-oriented product that can be added as a satellite position to enhance return potential when used in a strategic or tactical allocation.
- **Contrarian investment approach.** Fund management seeks to invest in equity securities of undervalued health care companies with the potential to appreciate as the companies become more fully valued and realize their growth potential.

### Investment Results


Average Annual Total Returns (%) as of Dec. 31, 2011

Period	Class A Shares Inception: 08/07/89		Class C Shares Inception: 03/01/99		Investor Class Shares Inception: 07/15/05	Class Y Shares Inception: 10/03/08	Style-Specific Index
	Max Load 5.50%	NAV	Max CDSC 1.00%	NAV	NAV	NAV	MSCI World Health Care Index
Inception	9.53	9.81	5.58	5.58	-	-	-
20 Years	7.11	7.42	-	-	-	-	-
15 Years	6.63	7.03	-	-	-	-	-
10 Years	2.00	2.58	1.90	1.90	2.58	2.66	3.13
5 Years	0.95	2.10	1.35	1.35	2.10	2.27	1.69
3 Years	9.49	11.58	10.76	10.76	11.58	11.86	10.04
1 Year	-1.60	4.14	2.42	3.42	4.18	4.42	9.46
Quarter	0.02	5.85	4.67	5.67	5.88	5.92	7.94

Performance quoted is past performance and cannot guarantee comparable future results; current performance may be lower or higher. Visit [invesco.com/performance](http://invesco.com/performance) for the most recent month-end performance. Performance figures reflect reinvested distributions and changes in net asset value (NAV). Investment return and principal value will vary, and you may have a gain or a loss when you sell shares. No contingent deferred sales charge (CDSC) will be imposed on redemptions of Class C shares following one year from the date shares were purchased. Performance shown at NAV does not include applicable CDSC or front-end sales charges, which would have reduced the performance. Investor Class shares have no sales charge; therefore, performance is at NAV. Performance shown prior to the inception date of Investor Class shares is that of Class A shares and includes the 12b-1 fees applicable to Class A shares. Class A share performance reflects any applicable fee waivers or expense reimbursements. Class Y shares have no sales charge; therefore, performance is at NAV. Performance shown prior to the inception date of Class Y shares is that of Class A shares and includes the 12b-1 fees applicable to Class A shares. Class A share performance reflects any applicable fee waivers or expense reimbursements. Returns less than one year are cumulative; all others are annualized.

Index source: Lipper Inc.

### Calendar-Year Total Returns (%)



### About risk

Securities issued by foreign companies and governments located in developing countries may be affected more negatively by inflation, devaluation of their currencies, higher transaction costs, delays in settlement, adverse political developments, the introduction of capital controls, withholding taxes, nationalization of private assets, expropriation, social unrest, war or lack of timely information than those in developed countries.

The fund's foreign investments may be affected by changes in the foreign country's exchange rates; political and social instability; changes in economic or taxation policies; difficulties when enforcing obligations; decreased liquidity; and increased volatility. Foreign companies may be subject to less regulation resulting in less publicly available information about the companies.

The fund's performance is vulnerable to factors affecting the health care industry, including government regulation, obsolescence caused by scientific advances and technological innovations.

The investment techniques and risk analysis used by portfolio managers may not produce desired results.

Fluctuations in the values of synthetic instruments may not correlate perfectly with the instruments they are designed to replicate. Some synthetic instruments are more sensitive to interest rate changes and market price

### Fund Facts

Nasdaq A: GGHCX C: GTHCX  
Investor: GTHIX  
Y: GGHYX

Total Net Assets \$1,030,932,737  
Total Number of Holdings 63  
Annual Turnover (as of 10/31/11) 37%

### Top Equity Holdings % of Total Net Assets

Roche Holding Ltd.	4.15
Gilead Sciences Inc.	3.98
CVS Caremark Corp.	3.43
Thermo Fisher Scientific Inc.	3.33
BioMarin Pharmaceutical Inc.	2.90
Aetna Inc.	2.71
UnitedHealth Group Inc.	2.70
Abbott Laboratories	2.65
Novartis AG	2.64
Bayer AG	2.59

Holdings are subject to change and are not buy/sell recommendations.

### Top Countries

United States	67.58
Switzerland	7.76
Ireland	6.21
Germany	3.95
Israel	2.54
United Kingdom	2.13
Brazil	2.06
Japan	1.92
France	1.01
Russia	0.19

Holdings are subject to change and are not buy/sell recommendations.

### Expense Ratios % Net % Total

Class A Shares	1.23	1.23
Class C Shares	1.98	1.98
Investor Class Shares	1.23	1.23
Class Y Shares	0.98	0.98

Per the current prospectus

## About risk (continued)

fluctuations than others.

Investor Class shares are available only to certain investors. See the prospectus for more information.

Class Y shares are available only to certain investors. See the prospectus for more information.

The fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

Neither MSCI nor any party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the data is permitted without MSCI's express written consent.

The MSCI World Health Care Index is an unmanaged index considered representative of health care stocks of developed countries. An investment cannot be made directly in an index.

**12-month forward and trailing P/E** are calculated using weighted harmonic averaging, which helps avoid extreme results that may occur due to small relative numbers in the denominator. It doesn't exclude extreme values; instead, it reduces the effect of outliers on the aggregate calculation. The **price/book ratio** is the market price of a stock divided by the book value per share.

**Return on equity (ROE)** is net income divided by net worth. The **median 12-Month Fwd. Growth Rate** is the percent change between the next twelve months' mean EPS estimate and the previous twelve months' actuals. The **three-year EPS growth rate** is a weighted average of each stock holding's growth rate in earnings per share (EPS). EPS is total earnings divided by the number of shares outstanding. This measurement is not a forecast of the fund's performance. The **five-year dividend growth rate** is the weighted average of each stock holding's annualized percentage rate of growth in dividend yield over five years. This measurement is not a forecast of the fund's performance. **Alpha** (cash adjusted) is a measure of performance on a risk-adjusted basis. **Beta** (cash adjusted) is a measure of relative risk and the slope of regression. **R-squared** (cash adjusted) expresses the proportion of variation in the return of one fund explained by the return of a benchmark. **Tracking error** measures the difference between returns of a portfolio and its benchmark index. The **up and down capture** measures how well a manager was able to replicate or improve on periods of positive benchmark returns and how severely the manager was affected by periods of negative benchmark returns. **Standard deviation** measures a fund's range of total returns and identifies the spread of a fund's short-term fluctuations.

All data provided by Invesco unless otherwise noted.

## External Comparisons Based on Total or Risk-Adjusted Return

### Morningstar Ratings and Rankings and Lipper Rankings

Class A Shares as of Dec. 31, 2011

	Overall	1 Year	3 Years	5 Years	10 Years
vs. Morningstar Health Category*					
A Shares (Load)	★★	N/A	★★	★★	★★
A Shares (Load Waived)	★★★	N/A	★★★	★★★	★★★
Number of Funds in Category	127	N/A	127	122	92
vs. Morningstar Health Category**		82%	70%	70%	70%
		(116 of 140)	(89 of 127)	(86 of 122)	(65 of 92)
vs. Lipper Global Health/Biotechnology Funds Category***		73%	41%	50%	71%
		(31 of 42)	(15 of 36)	(17 of 33)	(19 of 26)

\*Source: ©2012 Morningstar Inc. All rights reserved. The information contained herein is proprietary to Morningstar and/or its content providers. It may not be copied or distributed and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Ratings are based on a risk-adjusted return measure that accounts for variation in a fund's monthly performance, placing more emphasis on the downward variations and rewarding consistent performance.** With-load ratings include the effect of sales charges, loads and redemption fees. Load-waived ratings exclude sales charges, loads and redemption fees, and are only applicable to investors not subject to sales charges. The overall rating is derived from a weighted average of three-, five- and 10-year rating metrics, as applicable. Ratings are as of the most recent quarter end and are subject to change every month. A fund is eligible for a Morningstar rating three years after inception. The top 10% of funds in a category receive five stars, the next 22.5% four stars, the next 35% three stars, the next 22.5% two stars and the bottom 10% one star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) Ratings for other share classes may differ due to different performance characteristics. Past performance does not guarantee future results.

\*\*Source: Morningstar Inc. **Morningstar rankings are based on total return, excluding sales charges and including fees and expenses,** versus all funds in the category tracked by Morningstar.

\*\*\*Source: Lipper Inc. **Lipper fund percentile rankings are based on total returns, excluding sales charges and including fees and expenses,** and are versus all funds in the category tracked by Lipper.

### Portfolio Characteristics: Fund vs. MSCI World Health Care Index

Valuation Statistics			Equity Sector Breakdown		
	Fund	Index	Market Sector	Fund	Index
12-Month Forward P/E	13.19	11.37	Health Care	90.66	100.00
12-Month Trailing P/E	14.83	11.80	Consumer Staples	4.07	0.00
Price/Book (Wtd. Avg.)	3.38	3.59	Industrials	0.69	0.00
1-Year ROE (Wtd. Avg.)	15.30	20.11	Consumer Discretionary	0.00	0.00
12-Month Fwd. Growth Rate (Median) (%)	10.05	10.19	Energy	0.00	0.00
3-Year EPS Growth Rate (Wtd. Avg.) (%)	16.82	4.46	Financials	0.00	0.00
5-Year Dividend Growth Rate (Wtd. Avg.) (%)	21.50	11.81	Information Technology	0.00	0.00
Weighted Average Market Cap (\$MM)	32,870	75,230	Materials	0.00	0.00
Weighted Median Market Cap (\$MM)	17,011	56,283	Telecommunication Services	0.00	0.00
3-Year Standard Deviation	14.67	15.26	Utilities	0.00	0.00
Sources: Invesco, Compustat, Thomson Financial, MSCI, StyleADVISOR			Sources: Invesco, MSCI		
Statistics			Capitalization Breakdown		
Fund vs. Index	3 Years	5 Years		Fund	Index
Alpha (%)	2.58	0.58	Giant	25.59	62.99
Beta	0.88	0.98	Large	34.56	25.96
R-Squared	0.84	0.87	Mid	29.59	11.05
Tracking Error (%)	6.06	5.67	Small	7.29	0.00
Up Capture (%)	95.81	103.94	Micro	2.98	0.00
Down Capture (%)	88.15	101.15	Based on Morningstar capitalization ranges		
Source: StyleADVISOR; based on Class A shares			Geographic Diversification		
Asset Mix (%)			% of Total Net Assets		
	at 12/31/11	at 12/31/10	Region		
Domestic Common Stk	67.58	75.23	Europe		18.01
Int'l Common Stk	27.81	20.24	Asia		1.91
Cash	4.44	4.61	Latin America		2.06
Other	0.17	-0.08	Africa/Middle East		2.60
			North America		70.84
			Developed Market Exposure		93.11
			Emerging Markets Exposure		2.31
A negative value in Other is normally due to fund activity that has accrued or is pending settlement.					

## NOT FDIC INSURED | MAY LOSE VALUE | NO BANK GUARANTEE

Consider the investment objectives, risks, charges and expenses carefully before investing. Please read the prospectus carefully before investing. For this and more complete information about the funds, contact your financial advisor or visit [invesco.com/fundprospectus](http://invesco.com/fundprospectus).

Note: Not all products, materials or services available at all firms. Advisors, please contact your home office.

# Invesco Global Health Care Fund

Data as of Dec. 31, 2011

## Performance summary

- In the fourth quarter, the European debt crisis dominated headlines and created volatility in equity markets across the globe. However, the major equity markets still managed gains for the quarter, with all 10 sectors of the MSCI World Index achieving positive returns.
- The fund's class A shares at net asset value (NAV) compared favorably to its broad market benchmark, the MSCI World Index. However, the fund lagged its style-specific benchmark, the MSCI World Health Care Index, for the period. (Please see the returns table on page 1 for fund and index performance.)
- The fund's pharmaceutical holdings delivered a positive return, but lagged the overall industry within the MSCI World Health Care Index. The fund's significant underweight in pharmaceuticals also detracted from results relative to the index.
- The health care equipment and the life science tools and services industries detracted from relative and absolute results, while the fund's holdings in biotechnology and health care providers and services stocks had a positive effect on both absolute and relative results.

## Contributors to performance

- The largest contributor to results during the quarter was **CVS Caremark** (3.43% of total net assets), a company that operates as a traditional retail pharmacy as well as a mail order pharmacy benefits manager (PBM). During the quarter, the company reported solid quarterly results with revenue growth in both the retail and PBM segments. The company also raised its quarterly dividend by 30% and offered a positive outlook for 2012 earnings.
- **DaVita** (2.48% of total net assets), a leading dialysis provider in the U.S., was another key contributor. The company reported higher revenues and profits during the quarter, which bolstered shares.
- Another contributor was **Pharmasset Inc.** (1.25% of total net assets), a biotechnology company whose primary focus is developing oral treatments for hepatitis C. The company has a number of promising drug candidates, and its antiviral drug recently attained fast track status from the FDA. In November, Gilead Sciences made an \$11 billion cash bid for **Pharmasset**. The \$137 a share bid was at a significant premium, which sent **Pharmasset's** shares immediately higher following the announcement.

## Detractors from performance

- **Thermo Fisher Scientific Inc.** (3.33% of total net assets) was the largest detractor during the fourth quarter. The laboratory supplier makes and sells scientific instruments, laboratory equipment and diagnostic products. Despite an increase in its fiscal third quarter earnings, the company reduced its earnings and revenue outlook for the full year due to a marked slowdown in academic and government spending.
- **Hospira Inc.**, (0.00% of total net assets) which manufactures generic injectable pharmaceuticals and medication-management devices, also detracted from results. The company is addressing quality issues with its North Carolina manufacturing facilities, but the problems have proven costlier than anticipated. The company's shares plunged following a preliminary earnings release that reported a loss for its fiscal third quarter. We eliminated this holding during the quarter.
- **Baxter International Inc.** (2.26% of total net assets), a company that manufactures and markets drugs, devices and injectable therapies for a variety of medical conditions, also detracted. The company reported solid earnings during the quarter, but noted that margins were weaker than expected. Shares of the company have been negatively affected by investor concerns about pricing pressures for device makers as hospitals and health care providers seek to reduce costs.

## Top contributors and detractors

Contributors		Detractors	
	(%) of Total Assets		(%) of Total Assets
1. CVS/Caremark Corp.	3.43	1. Thermo Fisher Scientific Inc.	3.33
2. DaVita Inc.	2.48	2. Hospira Inc.	0.00
3. Pharmasset Inc.	1.25	3. Baxter International Inc.	2.26
4. Onyx Pharmaceuticals Inc.	1.12	4. Amarin Corp.	1.33
5. Aetna Inc.	2.71	5. Mako Surgical Corp.	0.70

## Positioning and outlook

- Overall we were net buyers during the quarter. We made new purchases in the biotechnology, health care equipment, and pharmaceutical industries. We sold holdings in the managed care industry, including **Coventry Healthcare** (0.00% of total net assets,) and we eliminated holdings in the industrial conglomerates as well as the life sciences tools industry.
- As stated above, we eliminated the fund's position in **Hospira** during the quarter. We added to positions in drug retailer **CVS/Caremark** and **Amarin** in the biotechnology industry (3.43% and 1.33% of total net assets, respectively).
- Despite these moves, the fund's overall positioning was unchanged. Relative to the benchmark, we maintained a significant underweight in large-cap pharmaceuticals as many of these firms face looming patent expirations with limited drug pipelines, which may result in modest (if any) earnings growth.
- We continue to emphasize specialty pharmaceuticals and biotechnology stocks based on their generally robust in-line portfolios, compelling pipelines and our view that many of these companies could be targets of ongoing consolidation.
- We are primarily focused on companies with new product cycles, less reimbursement risk and less competition.
- The fund is primarily invested in U.S. stocks, where we have found more companies that fit our fundamental selection criteria. The international allocation is focused mainly on European large-cap pharmaceuticals which have fewer patent expiration concerns than their U.S. counterparts.

The MSCI World Index (SM) is an unmanaged index considered representative of stocks of developed countries. An investment cannot be made directly in an index. Opinions expressed are those of the fund's portfolio management. Holdings are subject to change and are not buy/sell recommendations.